Nisa Investment Advisors LLC Has $150,000 Position in CareDx, Inc (NASDAQ:CDNA)

Nisa Investment Advisors LLC lessened its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 26.4% in the third quarter, Holdings Channel.com reports. The fund owned 4,805 shares of the company’s stock after selling 1,720 shares during the quarter. Nisa Investment Advisors LLC’s holdings in CareDx were worth $150,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CDNA. Caxton Associates LP lifted its stake in CareDx by 97.2% in the first quarter. Caxton Associates LP now owns 96,308 shares of the company’s stock valued at $1,020,000 after buying an additional 47,469 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of CareDx by 87.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 228,198 shares of the company’s stock valued at $2,417,000 after acquiring an additional 106,660 shares during the period. Renaissance Technologies LLC boosted its stake in CareDx by 6.2% during the 2nd quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company’s stock worth $23,492,000 after acquiring an additional 88,100 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in CareDx by 868.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company’s stock valued at $6,401,000 after purchasing an additional 183,823 shares during the period. Finally, Bamco Inc. NY bought a new stake in CareDx in the first quarter valued at approximately $13,025,000.

Wall Street Analyst Weigh In

CDNA has been the topic of a number of recent analyst reports. Wells Fargo & Company started coverage on shares of CareDx in a research report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price target on the stock. The Goldman Sachs Group boosted their target price on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Finally, BTIG Research dropped their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $29.60.

Insider Activity at CareDx

In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,561,179.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Alexander L. Johnson sold 21,557 shares of the firm’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the transaction, the insider now directly owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander L. Johnson sold 34,231 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the sale, the insider now directly owns 284,983 shares in the company, valued at $9,561,179.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 91,340 shares of company stock valued at $3,025,415. Corporate insiders own 4.90% of the company’s stock.

CareDx Stock Performance

NASDAQ:CDNA opened at $23.21 on Thursday. The stock has a 50-day simple moving average of $27.56 and a 200 day simple moving average of $20.97. CareDx, Inc has a 52-week low of $6.11 and a 52-week high of $34.84. The company has a market cap of $1.22 billion, a PE ratio of -8.60 and a beta of 1.80.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The company had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. During the same period last year, the business earned ($0.43) EPS. The business’s quarterly revenue was up 23.4% on a year-over-year basis. On average, research analysts predict that CareDx, Inc will post -0.83 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.